RC Compounding Services, LLC, Poland, OH

Is RC Compounding Services, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does RC Compounding Services, LLC hold a Ohio pharmacy license?

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018910 for RC COMPOUNDING SERVICES LLC, POLAND, OH, status NOT RENEWED, as of Nov 13, 2026.

Has RC Compounding Services, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Sep 12, 2019), 1 state referral letter (Sep 12, 2019) and 1 FMD-145 letter (Sep 12, 2019) for RC Compounding Services, LLC. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
RC Compounding Services, LLC
Location
Poland, OH
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 12, 2019
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as RC Compounding Services, LLC, a 503A facility, with 3 dated actions.

Document
Sep 12, 2019Warning letter close-outWarning Letter Close Out Issued 09/12/2019Not linked by FDA
Sep 12, 2019State referral letterReferral Letter to the Ohio State Board of Pharmacy Issued 09/12/2019fda.gov
Sep 12, 2019FMD-145 letterFMD-145 Letter Issued 09/12/2019FDA copy (archived)

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists RC Compounding Services, LLC, Poland, OH (FEI number 3009988995), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 14, 2015Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3009988995932600
Feb 7, 2013Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009988995818708

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 12, 2018 to Feb 16, 2018: 6 observations

Firm on the cover
RC Compounding Services, LLC, 3030 Center Rd C ITY. STATE. ZIP CODE. Country Poland, OH 44514 -2158
FEI number
3009988995
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
6751 Steger Drive Cincinnati, OH 45237-3097
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Personnel placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

On 02/12/2018, during the observation of production of Serum Tears in the ISO 5 Laminar Air Flow Hood, we observed an employee remove the caps from sterile droptainers and place the caps and containers in a pile, blocking the first pass ISO 5 air flow.

Observation 2

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

A. On 02/13/2018, we observed an employee use non-sterile <Redacted B4> to clean the ISO 5 Laminar Air Flow Hood. The employee was observed spraying a sterile wipe with non-sterile <Redacted B4> and then cleaning the work surface and sides inside of the ISO 5 Laminar Air Flow Hood.

id

B. Additionally, the employee noted above was observed spraying the outside ofthe ISO 5 Laminar Air Flow Hood and a chair in front of the opening of the ISO 5 Laminar Air Flow Hood, causing non-sterile <Redacted B4> to enter the ISO 5 Laminar Air Flow Hood.

Observation 3

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically,

On 02/12/2018, we observed an employee don non-sterile gloves; then put on sterile sleeves, touching them with the non-sterile gloves; then remove the non-sterile gloves, exposing bare hands; don sterile gloves; and then begin producing sterile drug products.

Observation 4

Non-sterilized and Non-depyrogenated equipment was used in sterile drug production.

Specifically,

A) While filling syringes ofsterile Testosterone Cypionate 200 mg for injection, an employee was observed making a makeshift heat shield to hold vials in the ISO 5 hood. The employee made the shield out of a sterile wipe that they rolled up on a non-sterile table in the ISO 7 anteroom and stapled it closed with non-sterile staples before putting it in the ISO 5 hood without any decontamination step.

B) On 02/13/2018, we observed an employee spray the pH electrode with <Redacted B4> water and then measure the pH of epinephrine solution in the ISO 7 cleamoom before using it in production of syringes of sterile Epinephrine/Lidocaine Intraocular Solution 0.01 mg/20 mg/ml. The <Redacted B4> water is poured into a non-sterile spray bottle in the ISO 7 anteroom before it is used to spray the pH electrode.

Observation 5

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically,

A. There are no air returns in the ISO 7 cleanroom or ISO 7 anteroom. Strong palpable air flow can be felt at the top, bottom, and sides of the doors exiting the cleanroom to the anteroom and the anteroom to the unclassified area.

B. There is no evidence that the ISO 7 anteroom was qualified while the wall mounted air

conditioner was in operation to demonstrate that the air conditioner does not affect the air quality in the ISO 7 anteroom.

Observation 6

You produced highly potent drugs without providing adequate containment, cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.

Specifically,

A. Sterile hazardous drugs such as tacrolimus, testosterone, and progesterone are produced in the same ISO 5 Laminar Air Flow Hood as all other sterile drug products with only a <Redacted B4> decontamination step in between hazardous and non-hazardous drug production.

B. Non-sterile hazardous drugs such as testosterone, estradiol, progesterone, and azathioprine are produced in the same safety hoods as all other non-sterile drug products with only a soapy water wash and <Redacted B4> decontamination step in between hazardous and non-hazardous drug production.

Name not shown x

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018910LICENSED PHARMACYRC COMPOUNDING SERVICES LLCPOLAND, OHNOT RENEWED

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.